Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19179846 | 0.89 | RIPK1 (0.37) | RIPK1SLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL16291788 | 0.88 | HRH3 (0.36) | RIPK1SLC6A3HRH3KDM1A | |
| SCHEMBL15141291 | 0.88 | HRH3 (0.36) | RIPK1SLC6A3HRH3KDM1A | |
| SCHEMBL6043785 | 0.86 | KDM4E (0.41) | RIPK1 | |
| SCHEMBL4099326 | 0.85 | RIPK1 (0.41) | RIPK1SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL3991385 | 0.85 | RIPK1 (0.41) | RIPK1SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL4114277 | 0.85 | RIPK1 (0.41) | RIPK1SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL22551225 | 0.83 | TSHR (0.41) | SLC6A2SLC6A4SLC6A3HTTKDM1A | |
| SCHEMBL17104487 | 0.77 | RIPK1 (0.43) | RIPK1SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL3117004 | 0.76 | RIPK1 (0.38) | RIPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | RIPK1 4754/4885SLC6A2 573/4885SLC6A4 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.